Osteoarthritis in 2020 and beyond: a Lancet Commission

Hunter, David J.; March, Lyn; Chew, Mabel

doi:10.1016/s0140-6736(20)32230-3

Cited by 498 publications

(371 citation statements)

References 8 publications

Supporting

Mentioning

307

Contrasting

Unclassified

Order By: Relevance

“…Mapping research to the CRRF, as conducted by Cochrane Rehabilitation, makes apparent what research topics are well addressed and which are neglected. This helps to drive researcher efforts (21,22), and guides editors decisions.…”

Section: Resultsmentioning

confidence: 99%

“…The CRRF presents the scope and areas of research enquiry that need to be addressed in order to build a comprehensive evidence base for clinical care, service organization, and health system strengthening to meet the needs of COVID-19 patients. Research frameworks have long been used by scientific communities to reflect consensus on research priorities (16)(17)(18), direct research funding (19,20) and drive research efforts (21,22) for entire sectors (23,24) or specific topics and sub specializations, including in rehabilitation (25-28). Reflecting these traditional functions, the CRRF has the specific aims to: This paper presents the methodology used to develop the CRRF, discusses how emerging evidence maps to the CRRF, and proposes how it can be best operationalized to meet its intended aims.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

“Rehabilitation Research Framework for Patients With COVID-19” Defined by Cochrane Rehabilitation and the World Health Organization Rehabilitation Programme

Négrini

Mills

Arienti

et al. 2021

Archives of Physical Medicine and Rehabilitation

View full text Add to dashboard Cite

The COVID-19 pandemic resulted in surge of research activity. Since its outset, efforts have been made to guide the rapid generation of research in medicine. There are gaps in some areas of rehabilitation research for patients with COVID-19. The development of a specific research framework might serve to help monitor the status of research (mapping), shape and strengthen research by pointing to under-investigated areas, and promote rehabilitation research in this context. This paper introduces and discusses the COVID-19 Rehabilitation Research Framework (CRRF) and presents the methodology used for its development. The questions have been developed among the World Health Organization Rehabilitation Programme, Cochrane Rehabilitation and the experts of its REH-COVER (Rehabilitation – COVID-19 Evidence-based Response) Action International Multiprofessional Steering Committee. The framework is divided into two parts and includes 20 questions organized in four groups: epidemiology, and evidence at the micro- (individual), meso- (health services) and macro- (health systems) level. The CRRF offers a comprehensive view of the research areas relevant to COVID-19 and rehabilitation that are necessary to inform best practice and ensure rehabilitation services and health systems can best serve the COVID-19 population. The collaboration between Cochrane Rehabilitation and the WHO Rehabilitation Programme in establishing the CRRF brought together perspectives from the health systems, health management and clinical evidence. The authors encourage researchers to use the CRRF when planning studies on rehabilitation in the context of COVID-19.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“Rehabilitation Research Framework for Patients With COVID-19” Defined by Cochrane Rehabilitation and the World Health Organization Rehabilitation Programme

Négrini

Mills

Arienti

et al. 2021

Archives of Physical Medicine and Rehabilitation

View full text Add to dashboard Cite

show abstract

“…Modifiable risk factors include obesity [181,189,[199][200][201][202], metabolic syndrome [181,[203][204][205][206], in particular diabetes mellitus [207][208][209] and habitual diet [187,210]. The condition is one of the most common causes of chronic pain and the most common cause of joint pain [211] with conservative estimates suggesting that there are approximately 500 million suffers worldwide [167,212]. OA affects ~13% of all over 50's (~7% in all ages; [213]) and has no cure [214][215][216][217][218] while being the 11th highest contributor to years lived with disability [159].…”

Section: Osteoarthritismentioning

confidence: 99%

Nutraceutical Alternatives to Pharmaceutical Analgesics in Osteoarthritis

Heffernan¹,

Conway²

2021

Pain Management - Practices, Novel Therapies and Bioactives

View full text Add to dashboard Cite

Chronic pain is a considerable health concern worldwide, effecting almost 30% of all European adults. Osteoarthritis (OA), a progressive pro-inflammatory condition, is one of the leading causes of chronic pain (effecting 13% of all those over 50 years, globally) and is the most common cause of joint pain. The prevalence of non-steroidal anti-inflammatory drug (NSAIDs) and analgesic use has been well studied and is abundant throughout the western world, with women being the greatest users and ibuprofen generally being the most reported NSAID. In the US, 65% of all OA patients are prescribed NSAIDs for pain management and form part of the current recommended strategy for OA clinical management. While some NSAIDs and analgesics are effective at improving pain and physical function, they come with significant and harmful side effects such as gastrointestinal complications, renal disturbances and severe cardiovascular events. Given these side-effects, any reduction in NSAID and analgesia use (and the resulting potentially harmful side effects) is of particular importance to OA public health. As such, a number of non-pharmaceutical alternatives (bioactive nutraceuticals) have been developed that may reduce NSAID and analgesia use while maintaining pain reduction and improvements in physical function. This chapter will discuss select nutraceuticals that are not currently in mainstream use but may have the potential to aid in the treatment of OA.

show abstract

“…According to the World Health Organization (WHO), OA affects millions of people worldwide. Recent estimates suggest that OA affects at least 7% of the global population, which represents more than 500 million people worldwide, with women disproportionately affected by the condition [10], especially after menopause [11][12][13].…”

Section: Osteoarthritis (Oa)mentioning

confidence: 99%

Neuroscience and Neuroimmunology Solutions for Osteoarthritis Pain: Biological Drugs, Growth Factors, Peptides and Monoclonal Antibodies Targeting Peripheral Nerves

Mobasheri

2021

NeuroSci

View full text Add to dashboard Cite

Neuroscience is a vast discipline that deals with the anatomy, biochemistry, molecular biology, physiology and pathophysiology of central and peripheral nerves. Advances made through basic, translational, and clinical research in the field of neuroscience have great potential for long-lasting and beneficial impacts on human and animal health. The emerging field of biological therapy is intersecting with the disciplines of neuroscience, orthopaedics and rheumatology, creating new horizons for interdisciplinary and applied research. Biological drugs, growth factors, therapeutic peptides and monoclonal antibodies are being developed and tested for the treatment of painful arthritic and rheumatic diseases. This concise communication focuses on the solutions provided by the fields of neuroscience and neuroimmunology for real-world clinical problems in the field of orthopaedics and rheumatology, focusing on synovial joint pain and the emerging biological treatments that specifically target pathways implicated in osteoarthritis pain in peripheral nerves.

show abstract

Osteoarthritis in 2020 and beyond: a Lancet Commission

Cited by 498 publications

References 8 publications

“Rehabilitation Research Framework for Patients With COVID-19” Defined by Cochrane Rehabilitation and the World Health Organization Rehabilitation Programme

“Rehabilitation Research Framework for Patients With COVID-19” Defined by Cochrane Rehabilitation and the World Health Organization Rehabilitation Programme

Nutraceutical Alternatives to Pharmaceutical Analgesics in Osteoarthritis

Neuroscience and Neuroimmunology Solutions for Osteoarthritis Pain: Biological Drugs, Growth Factors, Peptides and Monoclonal Antibodies Targeting Peripheral Nerves

Contact Info

Product

Resources

About